Sector News

Boehringer trims Connecticut workforce as sales suffer

February 17, 2015
Life sciences
Struggling with falling sales, Boehringer Ingelheim is trimming its workforce in Connecticut, which accounts for about 2,700 staffers altogether. 
 
A company spokesperson tells FierceBiotech that less than 5% of its staff at the Ridgefield site is affected by the move, or 2% of the total, but the company is looking to find new positions for some of the people involved in the cutback. 
 
“Boehringer Ingelheim is in the process of rebalancing its workforce in the U.S. to put the company in the best position for future growth,” the company says in a statement. 
 
The 294-acre Ridgefield campus is the site of one of three major R&D centers for Boehringer and serves as its U.S. headquarters. Boehringer announced plans for a $65 million facility to support R&D and production back in 2011.
 
Just weeks ago the company reviewed a possible move to sell its $2.3 billion generics unit and a facility in Columbus, OH. Last fall Boehringer also said it would trim hundreds of jobs in Germany to account for a 5% drop in sales and a reduced forecast for the second half of the year.
 
By John Carroll
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach